7 April 2020

The Chemical Immunology group from Martijn Verdoes, theme Nanomedicine, joined forces with two Organic Chemistry groups (Jeroen Codee and Dima Filippov) and a Chemical Biology group (Sander van Kasteren) from Leiden University, and Immunology groups at the AmsterdamUMC (Yvette van Kooyk) and the LUMC (Ferry Ossendorp) to form a consortium to develop new cancer vaccines.

Funding for this consortium was granted by the Institute for Chemical Immunology (ICI). Five PhD candidates will work in close collaboration to synthesize multimodal vaccine conjugates to specifically deliver tumor epitopes and immunomodulating adjuvants to dendritic cells with the aim to elicit specific T cell responses. Using state-of-the-art chemical strategies and super-resolution imaging techniques, conjugates bearing bioorthogonal trackable epitopes will be characterized at cell biological level.

This will provide valuable structure-activity relationship data when correlated to in vitro and in vivo immunological outcome, which will allow the consortium to rationally design further optimized vaccine conjugates.
 

Related news items


BRAINMODEL: precision medicine for brain disorders

25 October 2021

A team of researchers from Radboudumc, VU Amsterdam and other institutes is going to look for new and better ways to heal developmental disorders in the brain.

read more

How healthy is James Bond? - A flu to a kill No time to die: the pathogens surrounding secret agent 007

21 October 2021

James Bond made a total of 25 films between 1962 and 2021. In all those films, secret agent 007 washed his hands only twice, even though he often stayed in not so hygienic places with considerable health risks. Radboudumc researchers examined all the health risks in the 47 countries Bond visited.

read more

Surprisingly dominant cause underlying type I congenital defect of glycosylation

21 October 2021

Alex Garanto, Melissa Bärenfänger, Mirian Janssen, and Dirk Lefeber published a new study, identifying a surprisingly dominant genetic cause underlying type I congenital defect of glycosylation with neuromusculoskeletal phenotypes.

read more

Sensitive blood-test as a patient-friendly alternative for bone marrow-based cancer monitoring

20 October 2021

Hans Jacobs and Pieter Langerhorst, theme Cancer development and immune defense, and colleagues are one step closer to implementation of personalized diagnostics for bone marrow-based cancer monitoring.

read more

Register for peer coaching for RIMLS PhD candidates

20 October 2021

As a PhD candidate, you are in the lead of your own learning process, but you don’t need to do this alone. Register for the peer-coaching group ‘Stay in the lead – Together’ before 11 November 2021.

read more